The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review (original) (raw)
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
Pasquale Tondo
Journal of Clinical Medicine
View PDFchevron_right
Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
Sriram Sridhar
Respiratory Research, 2019
View PDFchevron_right
Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
Francesco Menzella
Journal of Asthma and Allergy, 2021
View PDFchevron_right
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
Richard Leigh
Journal of Allergy and Clinical Immunology, 2013
View PDFchevron_right
A Case Study Showing Benralizumab’s Effectiveness in Treating Uncontrolled Severe Eosinophilic Asthma that is Resistant to Omalizumab
Stelphy Stephen
International journal of science and healthcare research, 2022
View PDFchevron_right
Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
Carlos Martínez-Rivera
BMC Pulmonary Medicine, 2021
View PDFchevron_right
The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)
Botond Mátyás
Journal of Interdisciplinary Medicine, 2021
View PDFchevron_right
Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
Alessandro Vatrella
Journal of Asthma and Allergy
View PDFchevron_right
Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
Silvia Capobelli
Multidisciplinary Respiratory Medicine, 2021
View PDFchevron_right
Benralizumab substitution monotherapy in symptomatic relapsing asthma-dominant eosinophilic granulomatosis with polyangiitis
Mark Lazarovich
Immunopathologia Persa
View PDFchevron_right
Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?
Francesco Menzella
Expert Opinion on Biological Therapy, 2019
View PDFchevron_right
The clinical profile of benralizumab in the management of severe eosinophilic asthma
Francesco Menzella
Therapeutic advances in respiratory disease, 2016
View PDFchevron_right
Benralizumab: Resolution of Eosinophilic Pulmonary Vasculitis in a Patient With EGPA
Susanna Bormioli
Journal of Investigational Allergy and Clinical Immunology, 2021
View PDFchevron_right
Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis
Angelo Coppola
Respiratory Medicine Case Reports, 2020
View PDFchevron_right
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study
Sara Rizzoli
Journal of Asthma and Allergy
View PDFchevron_right
Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis
Francesco Menzella
Allergy, 2021
View PDFchevron_right
Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma
Ken Ohta
Allergology international : official journal of the Japanese Society of Allergology, 2017
View PDFchevron_right
The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies
DR MUNISH SAROCH
Current medical research and opinion, 2017
View PDFchevron_right
Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study
Carlos Martínez-Rivera
Respiratory Research
View PDFchevron_right
Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab
Katsunori Masaki
Asia Pacific Allergy, 2021
View PDFchevron_right
Benralizumab: Blowing Out Eosinophilic Pulmonary Vasculitis in A EGPA Patient
A. Vultaggio
Journal of investigational allergology & clinical immunology, 2021
View PDFchevron_right
Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use
Rossella Intravaia
F1000Research
View PDFchevron_right
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
Stefano Del Giacco
Frontiers in allergy, 2022
View PDFchevron_right
Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience
Maria Pia Foschino
Frontiers in Pharmacology, 2021
View PDFchevron_right
The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma
Izabela Kupryś-Lipińska
Pneumonologia i alergologia polska, 2016
View PDFchevron_right
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
ana sousa
New England Journal of Medicine, 2009
View PDFchevron_right
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Stefano Del Giacco
Respiratory Research, 2023
View PDFchevron_right
Off-Label Benralizumab in Severe Non-Necrotizing Eosinophilic Vasculitis following Critical COVID-19 Disease and in DRESS
Nicolae Miron
Journal of Clinical Medicine
View PDFchevron_right
Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)
Antolín Viña
BMC Pulmonary Medicine, 2021
View PDFchevron_right
Mepolizumab: a new drug programme for patients with severe eosinophilic asthma Authors
Aleksandra Kucharczyk
View PDFchevron_right
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
Emílio Pizzichini
The Lancet Respiratory Medicine, 2014
View PDFchevron_right
High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects
Karin Rosen
Journal of Allergy and Clinical Immunology, 2013
View PDFchevron_right